Given the generally lower valuations of HealthTech Ventures in Europe, what are the arbitrage opportunities for US investors in European ventures?

What does the new EU Medical Device Regulation mean for US and EU HealthTech ventures?

These and related questions will be explored by a panel of experts during the morning session of the Transatlantic HealthTech Investment Summit (THIS23).

In the afternoon session, there will be a focus on Venture Building by Europe's largest HealthTech Venture Builder (Dutch firm NLC), pitches by a selected group of HealthTech startups seeking funding (different TRL and round levels), a networking cocktail, and a VIP dinner.